In an attempt to confer long-term protective immunity, BALB/c female mice were immunized
intranasally with 10 (4) inclusion-forming units (IFU) of the Chlamydia trachomatis mouse …

Female BALB/c mice were immunized intranasally with the mouse pneumonitis biovar of
Chlamydia trachomatis and subsequently challenged in the ovarian bursa (C. trachomatis …

To vaccinate against a vaginal challenge with Chlamydia trachomatis, C3H/HeJ (H-2k) mice
were immunized intranasally (in) or intraperitoneally (ip) with 1× 106 inclusion forming units …

To establish the feasibility of inducing a protective immune response against a chlamydial
genital infection in animals with different genetic backgrounds, groups of C3H/HeN (H‐2k) …

ABSTRACT BALB/c mice were vaccinated by the intramuscular (im) and subcutaneous (sc)
routes with a native preparation of the Chlamydia trachomatis mouse pneumonitis (MoPn) …

Groups of BALB/c mice were orally immunized with Chlamydia trachomatis serovar
L2/434/Bu in order to characterize the nature and kinetics of the chlamydial antibody …

The ability to induce protection against a genital challenge was studied in BALB/c female
mice with three Chlamydia trachomatis mouse pneumonitis (MoPn) major outer membrane …

Chlamydia trachomatis is the leading cause of infection-induced infertility in women.
Attempts to control this epidemic with screening programs and antibiotic therapy have failed …

In all animal models for chlamydial infection, there is strong evidence for immunity to
reinfection; however, immunity is only complete (ie, preventing infection) in the short term. In …

There is currently no licensed vaccine against Chlamydia trachomatis, the leading cause of
sexually transmitted bacterial disease worldwide. Conventional vaccination attempts using …